Comparative Pharmacology
Head-to-head clinical analysis: PRINZIDE versus TRANDOLAPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRINZIDE versus TRANDOLAPRIL.
PRINZIDE vs TRANDOLAPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PRINZIDE is a combination of lisinopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Trandolapril is a prodrug that is hydrolyzed to its active metabolite trandolaprilat, which inhibits angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and preload/afterload reduction.
Oral, 1-2 tablets daily; each tablet contains 25 mg hydrochlorothiazide and 5 mg lisinopril. Adjust based on blood pressure response; maximum daily dose: 2 tablets.
1–2 mg orally once daily; maximum 4 mg once daily.
None Documented
None Documented
Clinical Note
moderateTrandolapril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid."
Clinical Note
moderateTrandolapril + Furosemide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide."
Clinical Note
moderateTrandolapril + Bumetanide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide."
Clinical Note
moderateLisinopril: terminal half-life 12 hours (effective half-life 30 hours due to prolonged ACE binding). Hydrochlorothiazide: terminal half-life 6-15 hours (biphasic, initial phase 2-4 h, terminal phase 6-15 h) with prolonged terminal phase in renal impairment.
Trandolapril: 6 hours; Trandolaprilat: 24 hours (terminal); effective half-life for ACE inhibition: ~24 hours allowing once-daily dosing
Lisinopril is excreted unchanged in urine (100% renal elimination); hydrochlorothiazide is excreted 95% renally as unchanged drug and 5% via bile.
Renal: 33% (as trandolaprilat); Fecal: 66% (as trandolapril and trandolaprilat); Biliary: minimal
Category C
Category D/X
ACE Inhibitor / Diuretic Combination
ACE Inhibitor
Trandolapril + Benzydamine
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Benzydamine."